Cargando…

Inclusion body myositis associated with Sjögren’s syndrome

Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren’s syndrome. We r...

Descripción completa

Detalles Bibliográficos
Autores principales: Misterska-Skóra, Maria, Sebastian, Agata, Dzięgiel, Piotr, Sebastian, Maciej, Wiland, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832753/
https://www.ncbi.nlm.nih.gov/pubmed/23233115
http://dx.doi.org/10.1007/s00296-012-2556-4
_version_ 1782291729841389568
author Misterska-Skóra, Maria
Sebastian, Agata
Dzięgiel, Piotr
Sebastian, Maciej
Wiland, Piotr
author_facet Misterska-Skóra, Maria
Sebastian, Agata
Dzięgiel, Piotr
Sebastian, Maciej
Wiland, Piotr
author_sort Misterska-Skóra, Maria
collection PubMed
description Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren’s syndrome. We report a case of a 47-year-old woman with headaches, symptoms of trigeminal neuralgia, progressive weakness in muscles of the upper and lower extremities and symptoms of dry eyes and mouth. On admission, creatine kinase level was increased to 6,956 IU/mL and lactate dehydrogenase (LDH) to 1,011 U/L in the serum. The increase in inflammatory factor (CRP, ESR) levels was not found. The diagnosis of inclusion body myositis associated with Sjögren’s syndrome was established on the basis of clinical picture and diagnostic tests. In this therapy, methotrexate and methylprednisolone were administered. The considerable improved muscle strength in the upper and lower extremities, improved speech and swallowing, disappearance of headache and reduction in CPK and LDH levels were found 8 months after establishing the diagnosis. Treatment with methotrexate and methylprednisolone improved the clinical symptoms and quality of life of this patient and may offer a therapeutic option for some patients with IBM and concomitant Sjögren’s syndrome.
format Online
Article
Text
id pubmed-3832753
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-38327532013-11-29 Inclusion body myositis associated with Sjögren’s syndrome Misterska-Skóra, Maria Sebastian, Agata Dzięgiel, Piotr Sebastian, Maciej Wiland, Piotr Rheumatol Int Short Communication Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies. It is a poorly understood disease, which affects skeletal muscles. IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjögren’s syndrome. We report a case of a 47-year-old woman with headaches, symptoms of trigeminal neuralgia, progressive weakness in muscles of the upper and lower extremities and symptoms of dry eyes and mouth. On admission, creatine kinase level was increased to 6,956 IU/mL and lactate dehydrogenase (LDH) to 1,011 U/L in the serum. The increase in inflammatory factor (CRP, ESR) levels was not found. The diagnosis of inclusion body myositis associated with Sjögren’s syndrome was established on the basis of clinical picture and diagnostic tests. In this therapy, methotrexate and methylprednisolone were administered. The considerable improved muscle strength in the upper and lower extremities, improved speech and swallowing, disappearance of headache and reduction in CPK and LDH levels were found 8 months after establishing the diagnosis. Treatment with methotrexate and methylprednisolone improved the clinical symptoms and quality of life of this patient and may offer a therapeutic option for some patients with IBM and concomitant Sjögren’s syndrome. Springer Berlin Heidelberg 2012-12-12 2013 /pmc/articles/PMC3832753/ /pubmed/23233115 http://dx.doi.org/10.1007/s00296-012-2556-4 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Short Communication
Misterska-Skóra, Maria
Sebastian, Agata
Dzięgiel, Piotr
Sebastian, Maciej
Wiland, Piotr
Inclusion body myositis associated with Sjögren’s syndrome
title Inclusion body myositis associated with Sjögren’s syndrome
title_full Inclusion body myositis associated with Sjögren’s syndrome
title_fullStr Inclusion body myositis associated with Sjögren’s syndrome
title_full_unstemmed Inclusion body myositis associated with Sjögren’s syndrome
title_short Inclusion body myositis associated with Sjögren’s syndrome
title_sort inclusion body myositis associated with sjögren’s syndrome
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832753/
https://www.ncbi.nlm.nih.gov/pubmed/23233115
http://dx.doi.org/10.1007/s00296-012-2556-4
work_keys_str_mv AT misterskaskoramaria inclusionbodymyositisassociatedwithsjogrenssyndrome
AT sebastianagata inclusionbodymyositisassociatedwithsjogrenssyndrome
AT dziegielpiotr inclusionbodymyositisassociatedwithsjogrenssyndrome
AT sebastianmaciej inclusionbodymyositisassociatedwithsjogrenssyndrome
AT wilandpiotr inclusionbodymyositisassociatedwithsjogrenssyndrome